Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.
Clinical trial NCT02732119 · COMPLETED
Trial details
- NCT number
- NCT02732119
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-06-14
- Primary completion
- 2020-02-25
- Enrollment
- 104
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.